DSM invests in biomaterials company Oxford Performance Materials
DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has invested $ 1.2 mln in the biomaterials company Oxford Performance Materials (OPM). This investment links on to DSM's innovation ambitions in the emerging business area (EBA) of biomedical materials, which is an important element of DSM's strategy Vision 2010 - Building on Strengths.
OPM markets biocompatible high performance polymers for use in medical device applications such as catheters and implantable devices. OPM's polymers offer advantages over metals in terms of improved biocompatibility, process flexibility, radiolucense and tailored formulations to meet biomechanical and design criteria.
Other news from the department business & finance
These products might interest you
Spinsolve Benchtop NMR by Magritek
Spinsolve Benchtop NMR
Spinsolve is a revolutionary multinuclear NMR spectrometer that provides the best performance
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
HYPERION II by Bruker
FT-IR and IR laser imaging (QCL) microscope for research and development
Analyze macroscopic samples with microscopic resolution (5 µm) in seconds
